GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$242.48
+33.65%Year over year
Reported trailing growth
- Revenue
- +46.9%
- EBITDA
- —
- EBIT
- +28.4%
- EPS
- -90.9%
- Free cash flow
- +230.5%
- Operating cash flow
- +325.8%
Forward estimates
Based on analyst estimates
- Revenue
- +18.0%
- EBITDA
- +166.4%
- EPS
- +119.7%
Three-year CAGR
- Revenue
- +21.5%
- EBITDA
- -52.7%
- EBIT
- +29.1%
- Net income
- -28.2%
- EPS
- -18.4%
- Free cash flow
- +20.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026